33 completed, 15 terminated, 11 active not recruiting, 11 recruiting. 83 Phase 2, 12 Phase 1, 12 Phase 3.
Follow Osteochondrodysplasias: new trials by email Literature Review of Osteochondrodysplasias trials Research Report on Osteochondrodysplasias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI) Bone marrow-derived mesenchymal stromal cells (MSCs) - Osteogenesis Imperfecta, Osteogenesis Imperfecta Type III | Phase 1 / Phase 2 | Not yet recruiting | Emory University | 12 | 2027-01-01 | 2026-05-08 |
| A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC Ficerafusp alfa, Pembrolizumab (KEYTRUDA®) - Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | Bicara Therapeutics | 160 | 2026-09-01 | 2026-10-13 |
| A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR) AGA2115 - Osteogenesis Imperfecta (OI) | Phase 2 | Recruiting | Angitia Biopharmaceuticals Guangzhou Limited | 48 | 2026-07-14 | 2026-09-22 |
| Gene-Modified Stem Cell Therapy for Children With Autosomal Recessive Osteopetrosis (ARO) FT024 - Osteopetrosis | Phase 1 / Phase 2 | Recruiting | Fondazione Telethon | 8 | 2026-06-20 | 2026-06-24 |
| Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia Infigratinib - Hypochondroplasia | Phase 2 | Enrolling by invitation | QED Therapeutics, a BridgeBio company | 135 | 2026-04-23 | 2026-08-26 |
| Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia BMN 333, Vosoritide Injection [Voxzogo] - Achondroplasia | Phase 2 / Phase 3 | Recruiting | BioMarin Pharmaceutical | 160 | 2026-04-20 | 2026-10-22 |
| Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN) AGA2115, Placebo - Osteogenesis Imperfecta (OI) | Phase 2 | Recruiting | Angitia Incorporated Limited | 80 | 2025-12-12 | 2026-11-04 |
| A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia ABSK061 - Achondroplasia | Phase 1 / Phase 2 | Not yet recruiting | Abbisko Therapeutics Co, Ltd | 110 | 2025-12-10 | 2025-12-22 |
| Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH) Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration - Achondroplasia | Phase 2 | Recruiting | QED Therapeutics, a BridgeBio company | 77 | 2025-11-19 | 2026-07-13 |
| An Interventional Study of Infigratinib in Children With Hypochondroplasia infigratinib 0.128 mg/kg/day, infigratinib 0.25 mg/kg/day - Hypochondroplasia | Phase 2 / Phase 3 | Enrolling by invitation | QED Therapeutics, a BridgeBio company | 24 | 2025-04-22 | 2026-07-16 |
| A Study of TYRA-300 in Children With Achondroplasia: BEACH301 TYRA-300 0.125 mg/kg, TYRA-300 0.25 mg/kg, TYRA-300 0.375 mg/kg - Achondroplasia | Phase 2 | Recruiting | Tyra Biosciences, Inc | 92 | 2025-03-04 | 2026-10-01 |
| FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo - Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Recruiting | Bicara Therapeutics | 650 | 2025-01-28 | 2026-10-29 |
| A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia. Navepegritide, Placebo for navepegritide - Achondroplasia | Phase 2 | Active not recruiting | Ascendis Pharma A/S | 25 | 2024-12-10 | 2026-10-13 |
| Study of the Efficacy and Safety of Etanercept Treatment in Patients With SAPHO Syndrome Etanercept, Placebo - SAPHO Syndrome | Phase 2 / Phase 3 | Recruiting | National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland | 60 | 2024-09-04 | 2026-04-13 |
| Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial Metformin Hydrochloride, betamethasone dipropionate, Pentoxifylline - Oral Submucous Fibrosis | Phase 1 / Phase 2 | Completed | Ziauddin University | 30 | 2024-08-12 | 2025-05-02 |
| A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections - Achondroplasia | Phase 2 | Active not recruiting | Ascendis Pharma Growth Disorders A/S | 22 | 2024-07-26 | 2026-02-18 |
| A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia Navepegritide, Placebo for Navepegritide - Achondroplasia | Phase 2 | Recruiting | Ascendis Pharma A/S | 72 | 2024-01-23 | 2026-04-08 |
| Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia SAR442501 - Osteochondrodysplasia | Phase 2 | Terminated | Sanofi | 16 | 2023-10-10 | 2026-06-25 |
| Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients Losartan 25 milligram capsule, Placebo - Radiation Induced Fibrosis | Phase 2 | Active not recruiting | Shaw Cancer Center | 43 | 2023-08-17 | 2026-06-18 |
| Radiographic Assessment of Bone Dimension Around Immediate Implants With FDBA and I-PRF vs FDBA Alone i-PRF and FDBA - Bone Density Increased | Phase 2 | Unknown | Krishnadevaraya College of Dental Sciences & Hospital | 20 | 2023-07-15 | 2024-07-30 |
Showing 20 of 83. Sign in to see all of them.
Achondroplasia (20) · Camurati-Engelmann Syndrome (18) · Osteogenesis Imperfecta (15) · Bone Diseases (13) · Dwarfism (13) · Osteopetrosis (13) · Musculoskeletal Diseases (11) · Genetic Diseases, Inborn (8) · Fibrous Dysplasia, Polyostotic (7) · Mucopolysaccharidosis IV (7) · Fibrous Dysplasia of Bone (6) · Bone Diseases, Developmental (4) · Anemia, Sickle Cell (3) · Fibrosis (3)
Bone Diseases, Developmental (79) · Musculoskeletal Diseases (72) · Bone Diseases (70) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (64) · Genetic Diseases, Inborn (56) · Skin and Connective Tissue Diseases (27) · Connective Tissue Diseases (24) · Endocrine System Diseases (16) · Collagen Diseases (15) · Metabolic Diseases (14) · Neoplasms (14) · Nutritional and Metabolic Diseases (14) · Neoplasms by Site (13) · Osteosclerosis (13)
vosoritide (6) · infigratinib (5) · setrusumab (5) · Alemtuzumab (4) · Busulfan (4) · Zoledronic Acid (4) · Cyclophosphamide (3) · Denosumab (3) · fludarabine (3) · fludarabine phosphate (3) · pembrolizumab (3) · AP 1903 reagent (2) · Cord Blood Stem Cell Transplantation (2) · Losartan (2) · Radiotherapy (2)
BioMarin Pharmaceutical (6) · QED Therapeutics, a BridgeBio company (5) · Ultragenyx Pharmaceutical Inc (5) · National Institute of Dental and Craniofacial Research (NIDCR) (4) · Ascendis Pharma A/S (3) · Ascendis Pharma Growth Disorders A/S (3) · Masonic Cancer Center, University of Minnesota (3) · AstraZeneca (2) · Bellicum Pharmaceuticals (2) · Bicara Therapeutics (2) · EMD Serono Research & Development Institute, Inc. (2) · Eli Lilly and Company (2) · Novartis Pharmaceuticals (2) · Pfizer (2) · University of Aarhus (2)
United States (53) · United Kingdom (27) · Australia (25) · France (23) · Canada (17) · Spain (17) · Italy (16) · Germany (13) · Denmark (12) · Portugal (10) · China (8) · Japan (8) · Belgium (7) · Ireland (7) · Poland (6)
Alison M Boyce, M.D. (3) · Paul Orchard, MD (2) · Alessandro M Gianni, MD (1) · Amir Ali Hamidieh, MD (1) · Andrea B Apolo, M.D. (1) · Andrea Necchi, MD (1) · Andrew Gilman, MD (1) · Andrew M Scott, MBBS (1)
PMID 38649657, PMID 31269546, PMID 32461347, PMID 42144862, PMID 22999294, PMID 24566706, PMID 24890385, PMID 25033066, PMID 28390753, PMID 29296761, PMID 30889272, PMID 31296256, PMID 31472446, PMID 31795071, PMID 32484386, PMID 32634238, PMID 32750127, PMID 33008091, PMID 33761804, PMID 34007848, PMID 34056870, PMID 34431071, PMID 35104665, PMID 35342457, PMID 35410255, PMID 36552855, PMID 36812441, PMID 36999533, PMID 37823031, PMID 37984383, PMID 38087967, PMID 38378678, PMID 38685585, PMID 38834319, PMID 38875119, PMID 39012717, PMID 39555818, PMID 41188357, PMID 41247754, PMID 41534675, PMID 41783511, PMID 42319555, PMID 42470570
2015 (2), 2016 (2), 2019 (2), 2005 (1), 2017 (1), 2018 (1), 2023 (1)